北京商报讯（记者 张君花）9月11日，北京商报记者了解到，上美股份宣布全球多肽美容科技开创者 Karl Lintner博士正式出任上美股份科学委员会首席科学顾问。根据公开资料，Karl Lintner博士就读于奥 地利维也纳大学的生物化学专业，专注研究胜肽三十多年，是全球首位将肽专利技术引入化妆品应用领 域的科学家。上美股份表示，Karl Lintner博士的加入，将为上美全球多肽技术布局提供前瞻性指导，为 上美科研团队提供技术建议与解决方案，与此同时，Karl Lintner博士也将作为上美全球化科研生态的重 要推动者，帮助上美股份对接国际顶尖科研机构和学术组织，建立跨国研发合作平台，促进全球优质科 研资源的整合与共享。 ...

Core Insights - The appointment of Dr. Karl Lintner as the Chief Scientific Advisor of Up Beauty marks a significant step in the company's global research and development strategy, integrating global scientific expertise with local market insights [3][10]. Group 1: Dr. Karl Lintner's Background and Role - Dr. Lintner is recognized as a pioneer in peptide technology within the cosmetics industry, having a PhD in biochemistry from the University of Vienna and over ten years of experience in peptide research [4][5]. - His contributions include successfully introducing peptide patent technology into cosmetics, transforming the beauty technology landscape [5][11]. - Lintner's collaboration with Up Beauty aligns with the company's vision of building a global research framework, enhancing its international cooperation capabilities [5][9]. Group 2: Strategic Implications for Up Beauty - The partnership with Dr. Lintner is expected to enhance Up Beauty's global competitiveness in peptide technology, providing a platform for innovation and collaboration with top international research institutions [13][14]. - This collaboration signifies a shift in the Chinese beauty industry towards a more systematic approach to research and development, moving from passive technology acquisition to proactive collaboration [16][17]. - Up Beauty aims to establish a "Chinese Original Ingredient" certification system, enhancing its role in setting industry standards and increasing its global influence [18][19]. Group 3: Market Context and Future Outlook - The Chinese beauty market is experiencing a surge in demand for effective products, positioning Up Beauty as a leader in connecting technological advancements with consumer needs [9][10]. - The collaboration is anticipated to accelerate the development of innovative peptide-based products, setting a benchmark for domestic brands in the anti-aging segment [11][13]. - The integration of global scientific insights with local market understanding is expected to elevate China's position in the global beauty research landscape [19][20].

Core Insights - The appointment of Dr. Karl Lintner as the Chief Scientific Advisor marks a significant step in the global R&D strategy of the company, enhancing its capabilities in peptide research and development in the beauty industry [1][2][3] Group 1: Dr. Karl Lintner's Background and Role - Dr. Lintner is recognized as a pioneer in peptide technology within the cosmetics industry, having successfully introduced peptide patent technology into cosmetic applications, which transformed global beauty technology [2][3] - His role will include providing forward-looking planning for the company's global peptide technology layout, assisting in building international research cooperation platforms, and integrating global high-quality research resources [6][7] Group 2: Strategic Importance of the Appointment - The collaboration signifies a shift in the Chinese beauty industry towards systematic competitiveness, moving from passive technology acquisition to proactive collaboration with top international scientists [7][8] - The partnership aims to establish a "Chinese Original Ingredient" certification system, enhancing the company's ability to set industry standards and improve its global influence in beauty technology [8] Group 3: Market Context and Opportunities - The Chinese beauty market is experiencing a surge in demand for efficacy-driven products, which aligns with the company's multi-brand strategy and market foundation, positioning it as a strong platform for technological breakthroughs [3][4] - The long-term investment in peptide research by the company has allowed it to catch up with international competitors, establishing a significant presence in the anti-aging segment [5][6]

Core Insights - The appointment of Dr. Karl Lintner as the Chief Scientific Advisor marks a significant step in the global R&D strategy of the company, enhancing its capabilities in peptide research and beauty technology [1][3][4] Group 1: Strategic Developments - The collaboration with Dr. Lintner signifies a new phase in the company's global R&D strategy, integrating global scientific wisdom with local market insights to boost the Chinese peptide research and beauty industry [3][10] - Dr. Lintner, a pioneer in peptide technology, brings over 20 years of experience and has been instrumental in introducing peptide patent technology into cosmetics, revolutionizing the beauty technology landscape [4][11] Group 2: Research and Development - The company has established a scientific committee to support international collaborations, aiming to create a cross-disciplinary and borderless research community, which aligns with Dr. Lintner's mission to realize scientific value [5][10] - The partnership will facilitate the establishment of a multinational R&D cooperation platform, enhancing the integration of top-tier global research resources and fostering collaborative innovation [13][16] Group 3: Market Positioning - The Chinese beauty market's dynamic nature and the company's leadership position provide a fertile ground for Dr. Lintner's expertise, allowing for the rapid iteration of technology in response to consumer demand for effective products [10][15] - The collaboration is expected to elevate the company's global standing in the cosmetics industry, enabling it to transform scientific breakthroughs into market-ready products that cater to local consumer needs [10][18] Group 4: Industry Impact - This partnership is poised to shift the Chinese beauty industry from passive technology adoption to proactive collaboration, enhancing the global competitiveness of domestic brands [15][16] - The initiative aims to establish a "Chinese Original Ingredient" certification system, promoting advancements in peptide technology and setting new industry standards, thereby increasing China's influence in global beauty technology [16][18]

香港交易及結算所有限公司及香港聯合交易所有限公司（「聯交所」）對本通告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不就因本通告全部或任何部分內容而產生或因倚賴該等內容 而引致之任何損失承擔任何責任。 Shanghai Chicmax Cosmetic Co., Ltd. 1. 審議及批准通函附錄一所載的建議取消監事會及修訂公司章程。 2. 審議及批准通函附錄二所載的建議修訂股東會議事規則。 3. 審議及批准通函附錄三所載的建議修訂董事會議事規則。 上海上美化妝品股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2145） 2025年第二次臨時股東會通告 茲通告上海上美化妝品股份有限公司（「本公司」）謹訂於2025年9月25日（星期 四）下午二時正假座中國上海市普陀區中山北路3300號B座25樓會議室舉行2025年第二 次臨時股東會（「2025年第二次臨時股東會」），以審議及批准以下決議案。除文義另有 所指外，本通告所用詞彙與本公司日期為2025年9月9日的通函（「通函」）所界定者具相 同涵義： 普通決議案 – 1 – 1. 審議及批准建議派發截至2025年6月30日止 ...

Shanghai Chicmax Cosmetic Co., Ltd. 除另有指明外，本代表委任表格所用詞彙與本公司日期為2025年9月9日的通函（「通函」）所界定者具有相同涵義。 | | 普通決議案 | （附註4） 贊成 | （附註4） 反對 | | --- | --- | --- | --- | | 1. | 審議及批准建議派發截至2025年6月30日止六個月的中期股息每股人民 | | | | | 幣0.5元。 | | | | 2. | 審議及批准通函附錄四所載的建議修訂本公司企業治理制度。 | | | | 3. | 審議及批准委任本公司執行董事。 | | | | | 特別決議案 | （附註4） 贊成 | （附註4） 反對 | | 1. | 審議及批准通函附錄一所載的建議取消監事會及修訂本公司公司章程。 | | | | 2. | 審議及批准通函附錄二所載的建議修訂股東會議事規則。 | | | | 3. | 審議及批准通函附錄三所載的建議修訂董事會議事規則。 | | | 上海上美化妝品股份有限公司 日期： 簽署 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2145） 適用於2025年9月25日（ ...

此乃要件 請即處理 閣下對本通函任何方面或應採取的行動如有任何疑問，應諮詢股票經紀或其他持牌證券交易商、銀行經 理、律師、專業會計師或其他專業顧問。 閣下如已售出或轉讓名下所有上海上美化妝品股份有限公司的股份，應立即將本通函連同隨附的代表委任 表格交予買主或承讓人、或經手買賣或轉讓的銀行、股票經紀或其他代理人，以便轉交買主或承讓人。 香港交易及結算所有限公司及香港聯合交易所有限公司對本通函的內容概不負責，對其準確性或完整性亦 不發表任何聲明，並明確表示，概不就因本通函全部或任何部分內容所產生或因依賴該等內容而引致的任 何損失承擔任何責任。 Shanghai Chicmax Cosmetic Co., Ltd. 上海上美化妝品股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2145） I. 2025年中期建議利潤分配方案； II.建議委任執行董事； III.建議取消監事會及修訂公司章程、股東會議事規則、 董事會議事規則及其他相關治理制度； 及 2025年第二次臨時股東會通告 本公司謹訂於2025年9月25日（星期四）下午二時正假座中國上海市普陀區中山北路3300號B座25樓會議 室舉行20 ...

中期報告 Interim Report 2025 中期報告 Contents 目錄 | Corporate Information | 公司資料 | 2 | | --- | --- | --- | | Business Overview and Outlook | 業務回顧及展望 | 6 | | Financial Summary | 財務概要 | 20 | | Management Discussion and Analysis | 管理層討論與分析 | 21 | | Corporate Governance and Other Information | 企業管治及其他資料 | 30 | | Independent Review Report | 獨立審閱報告 | 51 | | Interim Condensed Consolidated Statement | 中期簡明綜合損益表 | 53 | | of Profit or Loss | | | | Interim Condensed Consolidated Statement | 中期簡明綜合全面收益表 | 54 | | of Comprehensi ...

Group 1 - The stock of Shangmei Co., Ltd. (02145.HK) increased by over 5%, specifically by 5.42%, reaching a price of 98.2 HKD [1] - The trading volume amounted to 63.942 million HKD [1]

Core Viewpoint - The stock of Shangmei Co., Ltd. (02145) has risen over 5%, currently up 5.42% at HKD 98.2, with a trading volume of HKD 63.942 million. This increase is attributed to strong performance in the beauty category on Douyin, particularly for domestic brands like Han Shu, which has maintained its top position in sales for several consecutive months [1]. Group 1: Company Performance - In August, the GMV of the beauty category on Douyin exceeded RMB 20 billion, showing a year-on-year increase of 19.56% and a month-on-month increase of 21.46% [1]. - Han Shu has achieved sales exceeding RMB 700 million in August and has consistently ranked as the top beauty brand on Douyin for the first eight months of this year [1]. - Minsheng Securities highlights that Han Shu's main brand is experiencing strong growth, while other brands like Newpage are also seeing high growth, indicating a robust multi-brand strategy [1].